ICAAC 2015: Cempra CEO Sees Solithromycin Potential Beyond Infectious Diseases
This article was originally published in Scrip
Executive Summary
Cempra Inc. president and CEO Prabha Fernandes sees the company's lead drug candidate solithromycin as a pipeline-in-a-pill with potential beyond infectious diseases and she's willing to follow all plausible leads given the macrolide antibiotic's immunomodulatory effects.